- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04990869
Inflammation in COPD and the Effect of Nicotinamide Riboside (ICON)
Effects of Nicotinamide Riboside on the Airway Inflammation of Older Adults With COPD: A Randomized, Double-blind, Placebo-controlled Clinical Trial (NR-COPD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic obstructive pulmonary disease (COPD) is a major problem that affect more and more people worldwide with over three million deaths reported every year. COPD has been described as a disease of accelerated lung aging and is associated with oxidative stress and an increased inflammatory response to for instance viral infections. Therefore, in the current pandemic COPD patients are considered at high risk of COVID-19-related death and interventions in this group are crucial.
A major event in aging is the loss of nicotinamide adenine dinucleotide (NAD+)-a loss which may be important in promoting the pro-inflammatory environment that occur with aging and therefore possibly COPD. Indeed, NAD+ is emerging as a central metabolic molecule involved in multiple age-related pathways including inflammation and metabolic control. Recently, it was shown that age-associated NAD+ loss is due to macrophage M1-polarization, suggesting that NAD+ is required for macrophage activation, an event that is involved in the pulmonary inflammatory response. In humans, the therapeutic potential of boosting NAD+ levels through supplementation with one of its more bioavailable precursors has therefore gained attention.
Nicotinamide riboside (NR) is a NAD+ precursor and recent work suggests that aging can be ameliorated by even short-term treatment with NR. This vitamin B3-analog is naturally occurring, is readily taken up through oral administration and has been tested in human trials with few side effects. Notably, NR treatment in humans decreases circulating markers of inflammation. In addition, NAD+ replenishment may facilitate overall greater resilience of older patients considering the anti-aging effects of NR allowing these patients to better cope with infections. Interestingly, NR has been shown to return aging tissues to a younger state, possibly through augmentation of the sirtuin enzyme family-known to play an important role in almost all cellular functions. COPD patients have reduced sirtuin levels in the airways likely due to oxidative stress. Because sirtuins are NAD+-dependent, supplementation with NR could serve as a treatment option for patients with COPD through activation of sirtuins. In addition, NAD+ replenishment may facilitate overall greater resilience of older patients considering the anti-aging effects of nicotinamide riboside allowing these patients to better cope with infections.
The chosen dosage is 2 g per day given orally. This dose has been shown to be safe and tolerated. The dose will be split in two with ingestion of 1 g in the morning and 1 g in the evening. NR is a naturally occurring vitamin B3 analog produced by yeast and found in multiple food products at low concentration. Many organisms including humans cannot produce NR but have instead evolved methods to convert this into the central redox modulator NAD+.
The efficacy and safety of NR supplementation has been tested in a number of studies in both healthy middle-aged and older adults and in patients suffering from metabolic disease. Since this is a natural compound widely found in nature no subjects have yet developed allergic responses to the molecule, and repeated doses of up to 2 g orally per day have demonstrated an acceptable safety profile. No treatment-emergent adverse events have so far been reported for NR.
Older adults (age ≥ 60 years) with a diagnosis of COPD will be recruited from the Respiratory Medicine and Emergency departments at Bispebjerg Hospital, Denmark, and through advertisements on online websites (e.g. www.lungeforskning.dk). Lung-healthy controls will be recruited through online websites (e.g. www.forsøgsperson.dk). Potential participants will be asked if they want to participate in this trial and informed about the study procedures. If they agree and if they meet the inclusion and not the exclusion criteria, the subjects will be randomized to either the NR or placebo group. All subjects that give informed consent to participate will receive a study identification number.
Study endpoints will be assessed at baseline, after the 6-week treatment and follow-up after 18 weeks. Telephone follow-up will be conducted after 58 weeks. Endpoints include airway inflammation measured in sputum, untargeted RNA sequencing of nasal epithelial cells, DNA methylation and untargeted metabolomics in peripheral mononucleated cells, circulating inflammatory markers and NAD+ levels in whole-blood, in addition to clinical outcomes such as lung function (spirometry), chest x-ray and questionnaires.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark
- Respiratory Research Unit, Bispebjerg Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria COPD patients:
- Written informed consent.
- Age 60 or older.
- A body mass index (BMI) between 18.5-40.0 kg·m-2 and a weight ≥ 40 kg at enrolment.
- A diagnosis of chronic obstructive pulmonary disease (FEV1/FVC < 0.7).
- Smoking history of at least 10 pack years, but currently ex-smoker.
- Not using any inhalation steroids.
- A worsening of symptoms in relation to respiratory infections.
- Eosinophil count < 0.3 at inclusion or within 3 months.
Exclusion Criteria COPD patients:
- Exacerbation of COPD or severe airway infection within the last two months.
- Chronic use of supplements containing vitamin B or NR.
- Planned surgery during the course of the trial.
- Dementia/cognitive impairment or symptomatic psychiatric illness.
- Cancer diagnosis within last 5 years.
- Inability to speak and read Danish.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Concurrent enrollment in another clinical study involving an investigational treatment.
Inclusion Criteria Controls:
- Written informed consent.
- Age-, sex- and BMI-matched with COPD patients.
- No history of lung disease.
- Never-smoker.
Exclusion Criteria Controls:
- Chronic use of supplements containing vitamin B or NR.
- Planned surgery during the course of the trial.
- Dementia/cognitive impairment or symptomatic psychiatric illness.
- Cancer diagnosis within last 5 years.
- Inability to speak and read Danish.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Concurrent enrollment in another clinical study involving an investigational treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: COPD-NR
COPD patients receiving Nicotinamide Riboside
|
The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
|
Placebo Comparator: COPD-placebo
COPD patients receiving placebo
|
Placebo
|
Experimental: Control-NR
Lung-healthy controls receiving Nicotinamide Riboside
|
The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
|
Placebo Comparator: Control-placebo
Lung-healthy controls receiving placebo
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interleukin-8
Time Frame: 6 weeks
|
Measured in sputum
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NAD+ levels
Time Frame: 6 weeks
|
Measured in whole-blood
|
6 weeks
|
Interleukin-6
Time Frame: 6 weeks
|
Measured in plasma
|
6 weeks
|
Interleukin-10
Time Frame: 6 weeks
|
Measured in plasma
|
6 weeks
|
Tumor necrosis factor alpha
Time Frame: 6 weeks
|
Measured in plasma
|
6 weeks
|
C-reactive protein
Time Frame: 6 weeks
|
Measured in plasma
|
6 weeks
|
Matrix metalloproteinase-9
Time Frame: 6 weeks
|
Measured in plasma
|
6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Untargeted metabolomics
Time Frame: 6 weeks
|
Measured in peripheral blood mononucleated cells
|
6 weeks
|
Untargeted RNA sequencing
Time Frame: 6 weeks
|
Measured in nasal epithelial cells
|
6 weeks
|
DNA methylation
Time Frame: 6 weeks
|
Measured in peripheral blood mononucleated cells
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Morten Scheibye-Knudsen, MD/DMSc(PhD), University of Copenhagen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NR-COPD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
University Hospital, BrestRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Baylor Research InstituteNot yet recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy